Blood test guided treatment for newly diagnosed DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, CD20-positive diffuse large B-cell lymphoma (a type of blood cancer).
- Your disease is stage II, III, or IV (has spread beyond one lymph node area).
- You are age 18 or older.
- You have not had prior treatment for DLBCL, except for up to 14 days of steroids or one cycle of standard chemotherapy within the last 28 days.
- You are able to come for outpatient clinic visits and lab monitoring.
- Your organs (heart, liver, kidneys) are working well enough to receive standard chemotherapy.
- You are not pregnant or nursing, and you agree to use effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test to look for tumor DNA in people with high-risk B-cell lymphoma, to help predict if the lymphoma might spread to the brain or spinal cord. It may help doctors decide on extra treatments to prevent that spread.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests whether adding personalized, low-dose radiation therapy to standard chemotherapy improves outcomes for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The radiation plan is tailored based on how well your cancer responds to chemotherapy early on.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.